Sammy Chebon

1.1k total citations · 1 hit paper
22 papers, 731 citations indexed

About

Sammy Chebon is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Sammy Chebon has authored 22 papers receiving a total of 731 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 11 papers in Genetics and 4 papers in Immunology. Recurrent topics in Sammy Chebon's work include Hemophilia Treatment and Research (16 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (7 papers) and Platelet Disorders and Treatments (7 papers). Sammy Chebon is often cited by papers focused on Hemophilia Treatment and Research (16 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (7 papers) and Platelet Disorders and Treatments (7 papers). Sammy Chebon collaborates with scholars based in Switzerland, Germany and Japan. Sammy Chebon's co-authors include Michaela Lehle, Christophe Schmitt, Víctor Jiménez‐Yuste, Midori Shima, Nives Selak Bienz, Gallia G. Levy, Steven W. Pipe, Ido Paz‐Priel, Tiffany Chang and Elina Asikanius and has published in prestigious journals such as Blood, Statistics in Medicine and Current Medical Research and Opinion.

In The Last Decade

Sammy Chebon

21 papers receiving 713 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

2019 273 citations Steven W. Pipe, Midori Shima et al. The Lancet Haematology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sammy Chebon Switzerland	11	698	219	50	41	35	22	731
Nives Selak Bienz Switzerland	7	516 0.7×	157 0.7×	35 0.7×	30 0.7×	23 0.7×	10	536
L. Rusen United States	10	723 1.0×	187 0.9×	93 1.9×	24 0.6×	21 0.6×	20	742
Marianne Uguen Switzerland	7	373 0.5×	154 0.7×	45 0.9×	21 0.5×	15 0.4×	15	420
Herdis Larsen Denmark	4	300 0.4×	175 0.8×	82 1.6×	18 0.4×	13 0.4×	6	369
van Eys J United States	5	247 0.4×	82 0.4×	50 1.0×	14 0.3×	43 1.2×	8	320
Kasper Ck United States	6	354 0.5×	120 0.5×	48 1.0×	13 0.3×	35 1.0×	7	398
Sossana Delimpasi Greece	8	159 0.2×	85 0.4×	171 3.4×	10 0.2×	84 2.4×	13	243
Francesca Messa Italy	7	166 0.2×	67 0.3×	152 3.0×	7 0.2×	28 0.8×	28	255
Lourdes Hermosín Spain	7	142 0.2×	91 0.4×	81 1.6×	4 0.1×	12 0.3×	11	222
H. Kreipe Germany	5	124 0.2×	48 0.2×	42 0.8×	9 0.2×	28 0.8×	13	172

Countries citing papers authored by Sammy Chebon

Since Specialization

Citations

This map shows the geographic impact of Sammy Chebon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sammy Chebon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sammy Chebon more than expected).

Fields of papers citing papers by Sammy Chebon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sammy Chebon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sammy Chebon. The network helps show where Sammy Chebon may publish in the future.

Co-authorship network of co-authors of Sammy Chebon

This figure shows the co-authorship network connecting the top 25 collaborators of Sammy Chebon. A scholar is included among the top collaborators of Sammy Chebon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sammy Chebon. Sammy Chebon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kulasekararaj, Austin, Jarosław Czyż, Catherine Flynn, et al.. (2024). Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab or Eculizumab. Blood. 144(Supplement 1). 1323–1323. 1 indexed citations

Iglesia, Silvia de la, Richard Kelly, Austin Kulasekararaj, et al.. (2023). Biomarker Analyses in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 Trial. Blood. 142(Supplement 1). 4088–4088. 1 indexed citations

Callaghan, Michael U., Elina Asikanius, Michaela Lehle, et al.. (2022). Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3. Research and Practice in Thrombosis and Haemostasis. 6(6). e12782–e12782. 7 indexed citations

Kruse‐Jarres, Rebecca, Flora Peyvandi, Johannes Oldenburg, et al.. (2022). Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Advances. 6(24). 6140–6150. 30 indexed citations

Skinner, Mark W., Claude Négrier, Ido Paz‐Priel, et al.. (2021). The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 27(5). 854–865. 34 indexed citations

Schmitt, Christophe, Thomas Emrich, Sammy Chebon, et al.. (2021). Low immunogenicity of emicizumab in persons with haemophilia A. Haemophilia. 27(6). 984–992. 46 indexed citations

Oldenburg, Johannes, Huyen Tran, Flora Peyvandi, et al.. (2021). Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study. Haemophilia. 27(3). 398–407. 22 indexed citations

Callaghan, Michael U., Claude Négrier, Ido Paz‐Priel, et al.. (2020). Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 137(16). 2231–2242. 170 indexed citations

Callaghan, Michael U., Claude Négrier, Ido Paz‐Priel, et al.. (2020). Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4). Blood. 136(Supplement 1). 3–5. 4 indexed citations

10.

Oldenburg, Johannes, Midori Shima, Rebecca Kruse‐Jarres, et al.. (2020). Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatric Blood & Cancer. 67(10). e28474–e28474. 12 indexed citations

11.

Révil, Cédric, Markus Niggli, Sammy Chebon, et al.. (2019). Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Current Medical Research and Opinion. 35(12). 2079–2087. 21 indexed citations

12.

Pipe, Steven W., Midori Shima, Michaela Lehle, et al.. (2019). Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. The Lancet Haematology. 6(6). e295–e305. 273 indexed citations breakdown →

13.

Chebon, Sammy, Christel Faes, Ann De Smedt, & Helena Geys. (2019). Marginalized models for right-truncated and interval-censored time-to-event data. Journal of Biopharmaceutical Statistics. 29(6). 1043–1067.

14.

Kruse‐Jarres, Rebecca, Johannes Oldenburg, Elena Santagostino, et al.. (2019). Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non‐interventional study in a real‐world setting. Haemophilia. 25(2). 213–220. 28 indexed citations

15.

Jiménez‐Yuste, Víctor, Midori Shima, Ido Paz‐Priel, et al.. (2018). Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies. Blood. 132(Supplement 1). 1187–1187. 5 indexed citations

16.

Paz‐Priel, Ido, Tiffany Chang, Elina Asikanius, et al.. (2018). Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies. Blood. 132(Supplement 1). 633–633. 49 indexed citations

17.

Oldenburg, Johannes, Midori Shima, Rebecca Kruse‐Jarres, et al.. (2017). Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting. Blood. 130. 1089–1089. 2 indexed citations

18.

Jiménez‐Yuste, Víctor, Midori Shima, Katsuyuki Fukutake, et al.. (2017). Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-Label, Phase 3 Study (HAVEN 4). Blood. 130(Suppl_1). 86–86. 16 indexed citations

19.

Chebon, Sammy, Christel Faes, Frank Cools, & Helena Geys. (2016). Models for zero‐inflated, correlated count data with extra heterogeneity: when is it too complex?. Statistics in Medicine. 36(2). 345–361. 5 indexed citations

20.

Chebon, Sammy, Christel Faes, Ann De Smedt, & Helena Geys. (2015). Flexible modelling of simultaneously interval censored and truncated time-to-event data. Pharmaceutical Statistics. 14(4). 311–321. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact